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Abstract
Background: It is estimated that up to a third of patients on opioid agonist therapy (OAT) have attention deficit
hyperactivity disorder (ADHD). Treatment by ADHD medication, including a centrally acting stimulant (CAS) or
atomoxetine is one of the essential approaches. This study evaluates the use of dispensed ADHD medications in
the Norwegian OAT population in the period from 2015 to 2017. Types and doses of ADHD medications, co-
dispensations of other potentially addictive drugs like benzodiazepines, z-hypnotics, gabapentinoids, and non-OAT
opioids, as well as direct-acting antivirals (DAA) against hepatitis C infection, are investigated.
Methods: Information about all dispensed ADHD medication, OAT opioids, and the defined potentially addictive
drugs were recorded from the Norwegian Prescription Database. Dispensation rates, the types, and the doses of
dispensed ADHD medications were estimated by summarizing the number of dispensations, and the dispensed
doses. Logistic regression analyses were employed to assess the associations between ADHD medication, and OAT
opioid use, and dispensations of other potentially addictive drugs and DAAs against hepatitis C infection.
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Results: A total of 9235 OAT patients were included. The proportion of patients who were dispensed ADHD
medication increased from 3.5 to 4.6% throughout the study period. The three most dispensed CAS were short-
and intermediate-acting methylphenidate (55%), lisdexamphetamine (24%), and dexamphetamine (17%) in 2017.
Buprenorphine, rather than methadone, as OAT opioid (adjusted odds ratio: 1.6, CI: 1.2–2.1) was associated with
being dispensed ADHD medication. Among patients who received CAS and OAT opioids each calendar year, the
dispensed doses of methylphenidate increased from 63mg/day in 2015 to 76 mg/day in 2017 (p = 0.01). Sixty
percent of patients receiving ADHD medications were also dispensed other addictive drugs concomitantly in 2017.
Similar results were found in 2015 and 2016.
Conclusion: Co-prescription of ADHD medications was low among patients on OAT in Norway, considering a high
prevalence of ADHD in this patient group. On the other hand, concurrent dispensations of multiple addictive drugs
were common in this population. Understanding the underlying reasons for such prescribing is essential, and
research on how to optimize ADHD medication of patients with ADHD receiving OAT is needed.
Keywords: Opioid substitution treatment, Centrally acting stimulants, Hyperkinetic disorder, Attention deficit
hyperactivity disorder, Substance-related disorders, Dispensed drugs, Register data
Background
The strong association between opioid addiction and at-
tention deficit hyperactivity disorder (ADHD) is well
known [1]. Studies indicate that up to a third of patients
receiving opioid agonist therapy (OAT) meet the criteria
for ADHD [1–5]. Both opioids used in OAT and cen-
trally acting stimulants (CAS) may have properties asso-
ciated with euphoria and addiction. Current treatment
guidelines and previous reviews, therefore, recommend
stable psychosocial surroundings and close follow-ups by
health professionals in case of prescription of these
high-potent drugs [6–10]. The use of other reinforcing,
potentially addictive drugs such as benzodiazepines, z-
hypnotics, non-OAT opioids, and gabapentinoids should
be considered carefully to prevent adverse interactions
and risk of new addictions [11, 12]. However, about 50%
of patients receiving OAT and ADHD medication, in-
cluding CAS and atomoxetine, concomitantly discon-
tinue ADHD medication during the first 2 years after
the start of the treatment [13]. Reasons for discontinu-
ation include illicit drug use, side effects, and lack of
psychosocial stability [13]. Long-term therapy of ADHD
medication seems to have the highest chance of ad-
equate adherence when combining psychosocial treat-
ment with ADHD medication and OAT in the absence
of other reinforcing, potentially addictive drugs [14, 15].
Little is known about the prevalence of co-existing
ADHD and the utilization and the dose of prescribed
ADHD medication among patients with ADHD on
OAT. Additional use of other potentially addictive drugs
makes ADHD assessment and treatment with ADHD
medications more challenging. Psychosocial factors and
medical conditions among these patients may also
complicate diagnosis and the co-therapy with ADHD
medication. Therefore, studies show substantial inter-
country differences in co-existing ADHD prevalence
(5–30%) [2, 16], and variations in utilization and the dose
of prescribed ADHD medication [7, 9, 10, 17, 18]. There
is evidence that CAS have an effect by suppressing ADHD
symptoms among patients with drug use disorders
and comorbid ADHD [18]. Some studies also point
towards that the high-dosed CAS increases patients’
retention to treatment, and prevents discontinuation
[19, 20]. However, individual assessment taking into
consideration medical and psychosocial conditions will
be of particular interest to ensure a proper prescrip-
tion of CAS to patients on OAT with comorbid
ADHD.
During the past years, the guidelines for ADHD world-
wide recommend prescribing ADHD medication to
patients on OAT with comorbid ADHD and those with
other drug use disorders if they are abstinent from any
illegal drugs [7, 9, 10, 17]. However, the evidence support-
ing this recommendation is weak. In Norway, prescribing
ADHD medication has been recommending for patients
with ADHD on the OAT program since 2014 [21]. A total
of 7500 Norwegian patients are given OAT [22], and, in
2016, about 15% self-reported the use of illegal and legal
CAS during the last 4 weeks. Although the proportion
that was dispensed ADHD medication, on medical indica-
tion is uncertain after the guidelines were revised. To be
able to improve the treatment of ADHD, it is essential to
know more about the current prescription rates of ADHD
medications and the prescription patterns of other poten-
tially addictive drugs among patients on OAT who were
dispensed an ADHD medication.
Thus, this observational study was aimed to define
dispensation rates of attention deficit hyperactivity
disorder (ADHD) medications and potentially addict-
ive drugs among patients on opioid agonist therapy
(OAT) in the period from 2015 to 2017 in Norway.
The aims were to:
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1. define the dispensation rates of ADHD medication
and the types of ADHD medication dispensed per
calendar year.
2. assess whether the dispensations of ADHD
medication per calendar year were associated with
dispensations of benzodiazepines, z-hypnotics,
gabapentinoids, non-OAT opioids, as well as
direct-acting antivirals (DAA) against hepatitis C
infection, types of OAT opioids, the number of
dispensed OAT opioids, gender, and age in the
study period.
3. define the mean daily doses of dispensed ADHD
medications, and the dispensation rates of
benzodiazepines, z-hypnotics, gabapentinoids, and
non-OAT opioids in 2017 among patients who were
dispensed ADHD medication in the calendar year
throughout the study period.
Methods
Data source
All data were register data and were drawn from the
Norwegian Prescription Database (NorPD). From January
1, 2004, all pharmacies are obliged to submit data for all
dispensed drugs electronically to NorPD underlying the
Norwegian Institute of Public Health (www.norpd.no).
The NorPD contains information on all drugs dispensed
from pharmacies, except for drugs administrated at hospi-
tals, nursing homes, and outpatient clinics [23]. The Ana-
tomical Therapeutic Chemical (ATC) classification system
was employed in accordance with the World Health
Organization (WHO) standards per October 2018 [24].
Study population
All patients above 18 years of age who received at least
one dispensation of OAT opioids per calendar year, in-
cluding methadone, levomethadone, buprenorphine,
and buprenorphine-naloxone from January 1, 2015, to
December 31, 2017, were included. In addition, some
patients in palliative care use methadone tablets to
achieve pain relief. These patients were excluded by
identifying those who only were dispensed methadone
tablets without any dispensations of other OAT opioids
or methadone mixture in the period from January 1,
2004, to December 31, 2017.
Analysis strategy and statistical analyses
Definitions of drugs, including ADHD medications and
opioid agonist therapy opioids, the number of
dispensations of OAT opioids, and diagnoses
Attention deficit hyperactivity disorder medications were
defined as all CAS that had marketing authorizations in
Norway in the period 2015 to 2017, including racemic
amphetamine, dexamphetamine, methylphenidate, and
lisdexamphetamine. In addition, we included the non-
stimulant atomoxetine, which is also authorized and rec-
ommended in the treatment of ADHD according to
guidelines and reviews [6–10, 18, 25]. For methylphenidate,
the dispensations were classified by whether the formula-
tion was ‘short- or intermediate-acting’ or ‘long-acting.’
Long-acting methylphenidate included depot formulations
(Concerta®, Delmosart®, Equasym Depot®, or Methyl-
phenidate Sandoz®), while short- or intermediate-acting
methylphenidate included all other formulations (capsules
or tablets). All included OAT opioids, ADHD medica-
tions, non-OAT opioids, benzodiazepines, z-hypnotics,
gabapentinoids, including gabapentin and pregabalin, and
DAAs were categorized according to their ATC codes
(Additional file 1). The type of OAT opioid that patients
were dispensed was defined as the last type of OAT opioid
that was dispensed per calendar year.
The number of dispensed OAT opioids was defined as
the number of dispensations of any OAT opioid per pa-
tient per calendar year. The number of dispensations
was stratified according to four categories: 1–6, 7–12,
13–51, and ≥ 52 dispensations per calendar year. Age
was defined according to the patient’s age in the calendar
year and categorized into five groups: ≤ 25, 26–35, 36–45,
46–55, and ≥ 56 years.
All reimbursable and non-reimbursable ADHD medi-
cation dispensations were included. The prescribing
physician needs to specify the medical condition that is
treated by the particular drug, using codes from the 10th
revision of International Classification of Diseases (ICD-
10) or International Classification of Primary Care 2
(ICPC-2) to get public drug expenses reimbursed in
Norway. The diagnostic codes of reimbursed drugs are
recorded in the NorPD. Only two medical indications
are approved for ADHD medication expense reimburse-
ments in Norway: Hyperkinetic disorder/ADHD (ICD-10:
F90 and ICPC-2: P81) or narcolepsy (ICD-10: G47 and
ICPC-2: P81). For narcolepsy, only CAS are reimbursed.
The information on diagnostic codes for non-reimbursable
dispensations are not collected in the NorPD.
Analysis strategy according to the aims
One-year’s dispensation rates of ADHD medication
during the study period were assessed by summing all
patients who received at least one dispensation of an
ADHD medication per the calendar year. Furthermore,
patients were divided into two groups “all medical indi-
cations” and “ADHD” for the years in the study period.
The group named “ADHD” only included patients who
were dispensed ADHD medications with reimbursement
codes for ADHD. The group named “all medical indica-
tions” included all patients who received dispensations
of ADHD medications, either they were reimbursed or
not. Less than five patients were dispensed CAS on the
reimbursement code for narcolepsy in the study period.
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The association with being dispensed ADHD medica-
tion, or not adjusted for age, gender, type of dispensed
OAT opioids, the number of dispensed OAT opioids,
being dispensed benzodiazepines, z-hypnotics, gabapen-
tinoids, or non-OAT opioids were calculated per calen-
dar year in the study period. Age and the number of
dispensed OAT opioids were categorized according to
the predefined categories or groups per year. All dis-
pensed ADHD medication, and potentially addictive
drugs were identified and categorized into four drug
groups: “benzodiazepines or z-hypnotics,” “gabapenti-
noids,” “non-OAT opioids,” and “ADHD medication”
per year. For each group, categorical variables were cre-
ated by whether patients were dispensed one or more of
the drugs in the drug groups or not. Dispensations of
DAA were also included due to the frequent use of illicit
stimulant drugs in the OAT population and the fact that
DAA against hepatitis C infection has made treatment
more applicable for these patients. Patients were defined
to be dispensed treatment with DAA if they had at least
one dispensation of DAA from 2011 and until the end of
2015, 2016, or 2017, respectively.
The mean daily dose of each ADHD medication and
the dispensation rates of benzodiazepines or z-hypnotics,
gabapentinoids, and non-OAT opioids in 2017, were cal-
culated among patients with at least one dispensation of
ADHD medication and OAT, respectively, for each cal-
endar year in the study period. These patients were as-
sumed to have achieved medical continuity in their
ADHD treatment and follow up treatment according to
national guidelines. The mean daily doses of ADHD
medication were calculated by summarizing the total
volume of defined daily doses (DDD) of each drug that
was dispensed for each patient per year [26]. Further,
the number of DDDs dispensed per patient was con-
verted to milligrams according to WHO’s standards
(Additional file 2). The mean daily dose for each ADHD
medication was calculated by dividing the total dose (in
milligram) of each drug per year by 365.25 days. The
drug groups of each potentially addictive drugs were
used to calculate dispensation rates. Each drug group
was defined as categorical variables according to whether
patients were dispensed at least one drug defined into
the drug group or not during 2017.
Statistical analyses
Means, medians, percentiles, percentages, 95% confidence
intervals (CI), odds ratios (OR), and p-values are presented
when appropriate. Multivariable analyses for categorical
variables were performed by binary logistic regression.
Being dispensed ADHD medication, as well as OAT at
least once, respectively, during a calendar year, were de-
fined as a dependent variable in the logistic regression
model. Independent variables were age, gender, ‘the
number of dispensations of OAT opioids,’ ‘benzodiaze-
pines or z-hypnotics,’ ‘gabapentinoids,’ ‘non-OAT opioids,’
and ‘DAA.’ All these variables were defined categorically.
The level of statistical significance was defined as p < 0.05.
The Chi-square test and paired sample t-test were used to
estimate differences in dispensed mean daily doses of
ADHD medication in 2015 compared to 2017 among pa-
tients with at least one dispensation of ADHD medication
and OAT, respectively, during a calendar year throughout
the study period. All patients were censored from the
calendar year they died. SPSS version 24 was used for all
analyses.
Ethical considerations
The Regional Committee for Medical and Health Re-
search Ethics, REC vest, Norway, has approved the use
of registry data for this study (approval number 2018/
939/REK Vest, June 19, 2018). No informed consent
from included patients was necessary. The STROBE




A total of 9235 patients received at least one OAT
opioid from pharmacies in Norway in the period 2015 to
2017. In 2017, 69% were male, and the mean age was 45
years (Table 1). A total of 376 participants died during
the study period.
One-year prevalence and the types of dispensed ADHD
medications
The proportions of OAT patients who received at least
one dispensation of an ADHD medication increased from
3.5% in 2015 to 4.6% in 2017. A vast majority of them, i.e.,
74% received buprenorphine or buprenorphine-naloxone,
whereas the remaining 26% were dispensed methadone or
levomethadone. In 2017, the most dispensed CAS was
short- and intermediate-acting methylphenidate (55%),
followed by lisdexamphetamine (24%), dexamphetamine
(17%), long-acting methylphenidate (9%), and racemic am-
phetamine (2%) (Table 2ab). The non-stimulant atomoxe-
tine was dispensed in 6% of these patients. These findings
were substantially similar to the results in 2015 and 2016.
Dispensations of potentially addictive drugs to patients
receiving OAT opioids and ADHD medication
concomitantly
In the period from 2015 to 2017, being dispensed ADHD
medications were associated with being dispensed bupre-
norphine rather than methadone as OAT opioid (2017:
adjusted odds ratio (aOR): 1.6, 95% confidence interval
(CI): 1.3–2.1) (Table 3). Further, in 2017, being dispensed
ADHD medications were associated with being dispensed
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a non-OAT opioid (aOR 1.5, 95% CI: 1.1–1.9) and a DAA
against hepatitis C infection (aOR 1.6, 95% CI: 1.2–2.2).
The odds ratio (OR) of being dispensed DAA increased
steadily during the study period. Being dispensed ADHD
medications were not statistically associated with be-
ing dispensed gabapentinoids, benzodiazepines, or z-
hypnotics per year in the study period.
Mean daily doses of dispensed ADHD medications and
dispensation rates of other potentially addictive drugs
We identified 142 patients who received at least one dis-
pensation of ADHD medication per calendar year
throughout the study period. We found a substantial in-
crease in the dispensed mean daily doses of methylphen-
idate from 63mg in 2015 to 76mg in 2017 (p = 0.01)
(Fig. 1). The mean doses of other dispensed ADHD
medications were not statistically significantly different
in 2017 compared to 2015. However, the mean daily
dose of lisdexamphetamine increased from 21mg in
2015 to 83mg in 2017. The mean doses of amphet-
amine, dexamphetamine, methylphenidate, and lisdex-
amphetamine were near the highest recommended doses
for each drug, according to the European Medicines
Agency (EMA) [27]. Furthermore, 85 of the 142 patients
(60%) who were dispensed an ADHD medication per
year throughout the study period also received at least
one dispensation of z-hypnotics or benzodiazepines,
gabapentinoids, or non-OAT opioids in 2017 (Fig. 2).
The most frequent combination of dispensed drugs was
‘OAT opioid, ADHD medication, and benzodiazepines,
or z-hypnotics.’ Seven patients received ‘OAT opioid,
ADHD medication, benzodiazepines, or z-hypnotics,
gabapentinoids, and non-OAT opioids.’
Discussion
In the period 2015 to 2017, the proportion of patients
receiving ADHD medication in the OAT population in-
creased from 3.5 to 4.6%. Short- and intermediate-acting
methylphenidate and lisdexamphetamine were the most
frequently dispensed CAS. Dispensation of buprenor-
phine rather than methadone as an OAT opioid was
associated with being dispensed ADHD medication. In
2017, being dispensed non-OAT opioids and DAA
against hepatitis C infection were associated with being
dispensed ADHD medication. For four out of five
ADHD medication, the mean doses were near the high-
est recommended doses. Furthermore, the dose of
methylphenidate increased significantly throughout the
study period. Eighty-five of 142 patients who were dis-
pensed ADHD medication each year throughout the
Table 1 Baseline characteristics
2015 2016 2017
Patients 7958 7804 7709
Deaths 138 114 124
Patients, excl. Deaths 7820 7690 7585
OAT OAT + AMb OAT OAT + AMb OAT OAT + AMb
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
Dispensed ADHD medication – 274 (3.5) – 312 (4.1) – 349 (4.6)
Age
≤ 25 171 (2.2) 5 (1.8) 135 (1.8) 7 (2.2) 120 (1.6) 9 (2.6)
26–35 1551 (19.8) 81 (29.6) 1403 (18.2) 90 (28.8) 1333 (17.6) 84 (24.1)
36–45 2605 (33.3) 107 (39.1) 2508 (32.6) 118 (37.8) 2392 (31.5) 134 (38.4)
46–55 2544 (32.5) 69 (25.2) 2540 (33.0) 79 (25.3) 2548 (33.6) 97 (27.8)
≥ 56 949 (12.1) 12 (4.4) 1104 (14.4) 18 (5.8) 1192 (15.7) 25 (7.2)
Mean (SD) 43.9 (9.7) 41.0 (8.5) 44.5 (9.8) 40.8 (8.7) 45.0 (9.9) 41.8 (9.0)
Gender
Male 5430 (69.4) 193 (70.4) 5354 (69.6) 221 (70.8) 5245 (69.1) 254 (72.8)
Female 2390 (30.6) 81 (29.6) 2336 (30.4) 91 (29.2) 2340 (30.9) 92 (26.4)
OAT opioidsa
Methadone (included levomethadone) 3216 (41.1) 72 (26.3) 3066 (39.9) 74 (23.7) 2981 (39.3) 92 (26.4)
Buprenorphine (included combinations) 4604 (58.9) 202 (73.7) 4624 (60.1) 238 (76.3) 4604 (60.7) 257 (73.6)
ADHD Attention deficit hyperactivity disorder, AM ADHD medication (atomoxetine, racemic amphetamine, dexamphetamine, lisdexamphetamine, and
methylphenidate), NorPD Norwegian Prescription Database, SD standard deviation, and No Number of patients
a The last dispensed OAT opioid in the calendar year
b On all medical indications
The table displays the baseline characteristics of patients who were dispensed at least one OAT opioid per year in the period from 2015 to 2017
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study period were also dispensed benzodiazepines, z-
hypnotics, gabapentinoids, or non-OAT opioids in 2017.
Short- and intermediate-acting methylphenidate is the
most dispensed CAS throughout the study period. These
formulations, particularly the short-acting formulation,
are associated with euphoria and addiction compared to
long-acting formulation [18, 28]. However, the short-
and intermediate-acting methylphenidate might be pref-
erable in situations where more focus and concentration
is needed for shorter periods. In Norway, the reimburse-
ment for methylphenidate for adults is pre-approved for
intermediate-acting formulations as opposed to long-
acting formulations [29], which may explain that few
patients were dispensed long-acting formulations. A
study evaluating the dispensations of ADHD medica-
tions in the general population among the Nordic coun-
tries showed that Denmark and Norway, in contrast to
Finland, Iceland, and Sweden, were substantially dis-
pensed intermediate-acting rather than long-acting
methylphenidate in the treatment of ADHD [30]. The
Norwegian guidelines for treating ADHD do not
mention the formulation of methylphenidate to patients
on OAT in their recommendations [7]. However, a
European consensus report recommends long-acting
formulations of CAS to prevent misuse among patients
with drug use disorders and ADHD [18].
The proportion of patients who received ADHD medi-
cation increased in the inclusion period. Nevertheless,
the dispensation rates were still in the lower range of
what was expected. It is estimated that as much as a
third of patients with drug addictions in Norway have
comorbid ADHD [16], and the proportion of those with
opioid use disorder is supposed to be 11–33% [3–5]. As-
suming that 40–50% of patients with ADHD were dis-
pensed ADHD medication in the general population
[18], one would expect that about 4–16% of those with
opioid use disorder receive ADHD medication. Our find-
ings showed that only 4–5% of the patients on OAT also
were dispensed ADHD medication during the study
period. This might have several explanations. A consen-
sus report evaluating screening, diagnosis, and treatment
of patients with drug use disorders and ADHD, recom-
mends the use of CAS when potentially therapeutic pros
and cons are considered in advance [18]. In addition, the
Norwegian guidelines for ADHD discourage dispensa-
tions of ADHD medication to patients on OAT who
used other potentially addictive drugs concomitantly [7].
Furthermore, low dispensation rates of CAS may also be
explained by medical illnesses or psychosocial condi-
tions, and active illicit drug use, which may disturb the
diagnostic assessment of ADHD and delay pharmaco-
logical treatment.
Retention to treatment is generally challenging in the
treatment of drug addictions, particularly among pa-
tients with comorbid ADHD. Inadequate knowledge of
pharmacological properties of different ADHD medica-
tions may explain a low coverage. For example, unlike
CAS, the non-stimulant atomoxetine may need several
weeks to give optimal clinical response [18]. Late-onset
of the effect of atomoxetine or careful dose-escalation of
methylphenidates and amphetamines may conflict with
patient’s expectations on a quick reduction of ADHD
symptoms. In addition, removing factors leading to dis-
continuation of CAS treatment may play an essential
role in preventing relapse to illicit stimulant drug use
and sustained stimulant injections, as well as improving
the quality of life by keeping complications such as
Table 2 The proportion of patients on OAT were dispensed
ADHD medication categorized on medical diagnoses and types
of CAS
a)
Year 2015 2016 2017
All indications
Number of patients 274 312 349
ADHD medication No. %a No. %a No. %a
Methylphenidate 194 71 217 70 207 59
- short- and intermediate-actingb 182 66 206 66 193 55
- long-actingc 38 14 30 10 33 9
Dexamphetamine 63 23 64 21 60 17
Atomoxetine 23 8 26 8 21 6
Lisdexamphetamine 14 5 47 15 84 24
Racemic amphetamine < 5 0 < 5 1 8 2
b)
Year 2015 2016 2017
ADHD
Number of patients 223 270 312
ADHD medication No. %a No. %a No. %a
Methylphenidate 171 76 198 72 194 62
- short- and intermediate-actingb 163 73 190 70 182 58
- long-actingc 32 14 26 10 29 9
Dexamphetamine 45 20 55 20 53 17
Atomoxetine 12 5 19 7 16 5
Lisdexamphetamine 12 5 39 14 72 23
Racemic amphetamine < 5 < 5 < 5 < 5 7 2
ADHD Attention deficit hyperactivity disorder, ADHD medication =
atomoxetine, racemic amphetamine, dexamphetamine, lisdexamphetamine,
and methylphenidate, ICD-10 10th Revision of International Classification of
Diseases, ICPC2 International Classification of Primary Care 2, and OAT opioid
agonist therapy
a Per cent of patients who received OAT and CAS, b Include all tablets and
capsules with short- and intermediate-acting methylphenidate, c Include depot
formulations of methylphenidate (Concerta®, Delmosart®, Equasym Depot®, or
Methylphenidate Sandoz®)
The tables display patients on OAT who were dispensed an ADHD medication
in the period 2015 to 2017 categorized on a) all medical indications, and b)
ADHD (ICD-10 code: F90 or ICPC2 code: P81)
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hepatitis C infection low [31]. Integrating ADHD treat-
ment in OAT, or vice versa, maybe a way to facilitate
the diagnostics and treatment and improve follow-up
approaches among marginalized patients on OAT with
comorbid ADHD [32].
In this study, the mean doses of ADHD medications
were in the highest range of usual recommended doses.
The benefits of high-dose ADHD medication on the
treatment of ADHD in the OAT population are not
clear. Two placebo-controlled randomized trials, includ-
ing patients with ADHD and addictions to amphet-
amines or cocaine, have found a decrease of ADHD
symptoms by using doses up to 180 mg methylphenidate
[19] and 80mg racemic amphetamine daily compared to
placebo [20]. The former study [19] also found that
high-dose of methylphenidate reduced relapse to illicit
stimulant use and contributed to higher retention in
treatment. Previous research has also confirmed similar
findings [33]. The latter study [20], evaluating racemic
amphetamine to placebo, showed that doses of 60 mg
and 80mg racemic amphetamine per day, respectively,
inhibited cocaine-related craving. Although, a dose of
80 mg racemic amphetamine did not seem to reduce
ADHD symptoms more than a dose of 60 mg per day.
Overall, one can assume that using higher doses of me-
thylphenidate or racemic amphetamine may improve the
effect of these medications on ADHD by keeping pa-
tients in treatment, reducing the craving for illicit stimu-
lant drugs, as well as by alleviating ADHD symptoms.
The proportion of patients who were dispensed lisdex-
amphetamine increased significantly from 2015 to 2017.
In addition, the mean dose rose markedly in the same
period, although it was not statistically significant. A
meta-analysis evaluating the efficacy, acceptability, and
tolerability of ADHD medication among patients with
ADHD without drug addiction favored amphetamines as
Table 3 Logistic regression analyses of variables associated with dispensed ADHD medication and OAT
2015 2016 2017
Dispensed ADHD medication N = 274 N = 312 N = 349
Not dispensed ADHD medication N = 7546 N = 7378 N = 7236
Crude OR Adjusted OR
(95% CI)
Crude OR Adjusted OR
(95% CI)
Crude OR Adjusted OR
(95% CI)
Age
- ≤ 25 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
- 26–35 1.8 1.8 (0.7–4.5) 1.3 1.3 (0.6–2.9) 0.8 0.8 (0.4–1.7)
- 36–45 1.4 1.5 (0.6–2.7) 0.9 1.0 (0.5–2.2) 0.7 0.7 (0.4–1.5)
- 46–55 0.9 1.0 (0.4–2.6) 0.6 0.7 (0.3–1.6) 0.5 0.5 (0.2–1.0)
- ≥ 56 0.4 0.5 (0.2–1.4) 0.3 0.4 (0.2–0.9) 0.3 0.3 (0.1–0.6)
Gender
- Female 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
- Male 1.1 1.0 (0.8–1.4) 1.1 1.0 (0.8–1.3) 1.2 1.2 (1.0–1.6)
The number of dispensations of OAT opioids per calendar year
- ≥ 52 1.0 (ref.) 1.0 (ref.) 1.00 (ref.) 1.0 (ref.) 1.0 (ref.) 1.00 (ref.)
- 13–51 0.9 1.0 (0.7–1.4) 0.7 0.8 (0.6–1.2) 1.1 1.1 (0.8–1.7)
- 7–12 0.7 0.8 (0.5–1.3) 0.8 0.9 (0.6–1.3) 1.3 1.3 (0.9–2.0)
- 1–6 0.7 0.7 (0.4–1.2) 0.9 1.0 (0.7–1.6) 1.0 1.0 (0.6–1.7)
OAT opioidsa
- Methadone (incl. Levomethadone) 1.0 (ref.) 1.00 (ref.) 1.00 (ref.) 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
- Buprenorphine (incl. combinations) 2.0 1.7 (1.3–2.3) 2.2 1.9 (1.4–2.5) 1.9 1.6 (1.3–2.1)
Dispensed opioids (excl. OAT opioids) 1.0 1.1 (0.8–1.5) 1.0 1.1 (0.8–1.5) 1.4 1.5 (1.1–1.9)
Dispensed gabapentinoids 0.8 0.9 (0.5–1.4) 1.2 1.2 (0.8–1.7) 1.1 1.0 (0.7–1.4)
Dispensed benzodiazepines and/or z-hypnotics 0.8 1.0 (0.7–1.2) 0.8 0.9 (0.7–1.2) 1.0 1.0 (0.8–1.3)
Dispensed DAA 0.8 1.0 (0.5–2.1) 1.1 1.4 (0.9–2.3) 1.4 1.6 (1.2–2.2)
ADHD Attention deficit hyperactivity disorder, ADHD medication Atomoxetine, racemic amphetamine, dexamphetamine, lisdexamphetamine, and
methylphenidate, CI confidence interval, DAA direct-acting antivirals against hepatitis C infection, and OAT opioid agonist therapy
a The last OAT opioid was dispensed during a calendar year recorded in the Norwegian Prescription Database
The table displays odds ratios for each independent variable among patients who were dispensed ADHD medication (dependent variable) and OAT. For example,
the adjusted odds of being dispensed opioids in 2017 was 1.5 among patients who were dispensed ADHD medication. Each independent variable is stated as
crude (unadjusted) and adjusted for each calendar year. Italics display significant values
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Fig. 1 (See legend on next page.)
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the first drug group of choice in the short-term treat-
ment of ADHD in adults [25]. By comparing methyl-
phenidate and amphetamines, the latter was more
efficacious and showed higher acceptability (i.e., fewer
patients leaving the study). National Institute for Health
and Care Excellence (NICE) guidelines [9] and a consen-
sus report [18] evaluating patients with drug addictions
and ADHD recommend methylphenidate or lisdexam-
phetamine as the first drugs of choice in the treatment
of ADHD in adults. A risk assessment of the potential of
misuse of lisdexamphetamine and methylphenidate has
been completed by the WHO, which pointed towards
that methylphenidate and lisdexamphetamine still have
low harmful profiles compared to other stimulants such
as racemic amphetamine and methamphetamine in
treatment of ADHD [34]. The use of ADHD medication
in the Norwegian OAT population was in line with these
recommendations. In addition, it is essential to mention
that the lisdexamphetamine named Aduvanz® was
granted the Norwegian marketing authorization in
September 2017, and the upcoming facilitation in the
pre-approved reimbursement of lisdexamphetamine was
introduced in October 2018 [35]. These changes may
also explain some of the increasing dispensation rates
found in this study.
Eighty-five of 142 patients who were dispensed ADHD
medication and OAT opioids concomitantly received ei-
ther benzodiazepines, z-hypnotics, gabapentinoids, or
(See figure on previous page.)
Fig. 1 Doses of dispensed ADHD medication among patients who received OAT opioids from 2015 to 2017. Legends: ADHD = Attention deficit
hyperactivity disorder, ADHD medication = atomoxetine, racemic amphetamine, dexamphetamine, lisdexamphetamine, and methylphenidate,
CI = confidence interval, and Df = degrees of freedom. 1) Paired-samples t-test, df = 87, 2) Paired-samples t-test, df = 79, 3) Paired-samples t-test,
df = 10, 4) Paired-samples t-test, df = 26, 5) Paired-samples t-test, df = 5, and 6) Paired-samples t-test, df = 4. * = Upper recommended doses
according to The European Medicines Agency (EMA) per July 2019, ** = Calculation of the differences in mean daily doses between 2015 and
2017, *** = Upper recommended daily dose of short- and intermediate-acting methylphenidate according to the EMA, and **** = Include short-
and intermediate-acting methylphenidate (tablets or capsules), not depot formulations. The figure displays the mean daily doses of each
dispensed ADHD medication among patients who were dispensed at least one dispensation ADHD medication and OAT opioid, respectively,
each calendar year in the study period from 2015 to 2017
Fig. 2 Patients on ADHD medication who were dispensed other potentially addictive drugs in 2017. Legends: ADHD = Attention deficit
hyperactivity disorder, ADHD medication = atomoxetine, racemic amphetamine, dexamphetamine, lisdexamphetamine, and methylphenidate,
BZD = benzodiazepines, GAB = gabapentinoids, OAT = Opioid agonist therapy, OPI = non-OAT opioids, and z-HP = z-hypnotics. The figure displays
dispensations of BZD, GAB, OPI, and z-HYP in 2017 among patients who were dispensed at least one dispensation of ADHD medication and OAT
opioids each calendar year in the period from 2015 to 2017. Eighty-five patients were dispensed BZD or z-HP, GAB, or OPI in this population
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non-OAT opioids at least as frequent as in the
remaining OAT population not were dispensed ADHD
medications in 2017. Our findings confirm previous
studies on the OAT population, showing that about half
of patients on OAT were dispensed other potentially ad-
dictive drugs [11, 36]. The fact that a substantial propor-
tion of patients were dispensed CAS concomitant with
dispensations of other potentially addictive drugs may
point towards the need to improve the prescribing prac-
tice of addictive drugs in this comorbid population in
order to keep the risk of adverse interactions low [11,
12, 37]. On the other hand, the prevalence of psychiatric
and somatic comorbidities in OAT is high [38–40], and
it may predict the high dispensation rates of potentially
addictive drugs when these comorbidities are treated. In
some cases, prescribing potentially addictive drugs may
be used to keep the patients completely abstinent from
illicit potentially addictive drugs if health professionals
follow up strictly, and the prescribing practices are con-
sidered proper [14, 15].
Strengths and limitations
The use of national registry data has some clear
strengths, by capturing whole cohorts of the studied
populations. Pharmacy records are considered more
valid than both medical records and data collected from
questionnaires and interviews. Because practically all dis-
pensed drugs are registered in the NorPD database,
completeness, and precision of all received information
is high, and the potential for information biases is low.
This study also had some limitations. First, because
non-reimbursed dispensations of ADHD medication
were not received through the Norwegian Health
Economics Administration (HELFO), the medical indica-
tions for these dispensations are not available for the re-
searchers through NorPD. Further, gabapentinoids,
benzodiazepines, z-hypnotics, and non-OAT opioids
have different medical indications, and the indications
have not been evaluated in this study. Second, the num-
ber of dispensed OAT opioids may be incompletely reg-
istered by the pharmacies. The self-reporting survey of
OAT in Norway in 2017 showed that the mean fre-
quency of dispensations of OAT opioids was four times
a week [22]. This finding may indicate that the number
of dispensations is underestimated. Third, the NorPD
only receives information about dispensed drugs, and we
cannot know whether the drugs have been consumed.
All addictive drugs are coveted for illegal consumption,
and the drugs may be re-distributed. Illicit use is com-
mon in this population and cannot be covered using
register data. Fourth, slightly less than 10% of OAT opi-
oids are dispensed in addiction specialist outpatient
clinics, and those are not necessarily registered in the
NorPD. Some of these outpatient clinics order OAT
opioids directly from pharmacies without linking to a
personal identification number. These patients were
missed in this study, and those could have higher dis-
pensation rates of addictive drugs than patients included
in this study [22].
Conclusion
Co-prescribing of CAS and atomoxetine was low in the
OAT population in Norway, relative to the expected
prevalence of ADHD in this patient group. Considering
that up to a third of the OAT population is estimated to
have ADHD, only 3.5 to 4.6% of patients received both
ADHD medication and OAT opioids in Norway in the
period from 2015 to 2017. Furthermore, 85 of 142 OAT
patients who were dispensed ADHD medication each
year throughout the study period were dispensed at least
one dispensation of other potentially addictive drugs
concomitantly in 2017. Generally, the polydrug use, in-
cluding CAS, OAT, and other potentially addictive
drugs, may lead to adverse side effects; however, a treat-
ment combining several potentially addictive drugs in
OAT patients using CAS has only been scarcely studied.
Randomized-controlled trials evaluating ADHD medica-
tion in different doses are needed to improve the treat-
ment of ADHD in the OAT population.
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